Alan O. Trounson, embryonic stem cell research and invitro fertilization specialist, from Australia, has been nominated as president of the California Institute for Regenerative Medicine (CIRM), that is at the top of California’s stem cell program worth $3 billion.

Mr. Trounson has a glorious record in research & investigation, management skills and confronting Australia's controversial politics circling embryonic stem cell research.

Trounson is well-known through-out the world for his work in stem cell investigation and human fertilization.

A new research showed that using the birth control pill cut down the overall woman’s risk of developing cancer.

A study at the University of Aberdeen in Scotland analyzed records from a 36-year study, which discovered that any increased risk of breast and cervical cancer related to the use of pill seems to be wiped out by long-term protection from other types of cancers.

The cancer risk was up to 12% lower among those women who had used up the contraceptive pill.

Washington, Sept 16: Researchers at RTI International and the University of North Carolina at Chapel Hill have found that moderate financial incentives could promote employee weight loss.

In the study, more than 200 participants were recruited from the employees at one university and three community colleges in North Carolina.

Participants were arbitrarily assigned to be given no money, 7 dollar per percentage point of weight lost or 14 dollar per percentage point of weight lost, during the first three months.

Washington, Sept 16: Researchers at the New England Research Institute have found that one out of four men over 30 have low testosterone levels, but only one out of every 20 men have clinical symptoms linked to such a deficiency.

The study suggests that as men age, they are more likely to experience symptoms such as lack of sex drive and erectile dysfunction as a result of low levels of testosterone.

Washington: The U.S. Food and Drug Administration has approved 15 new blood typing examinations intended to perk up the safety of blood transfusion.

The tests that were previously unavailable in the US are called blood grouping reagents.

The FDA has stated that the tests find out the blood type of blood donors, a vital step in guaranteeing safe blood transfusion for patients. If incompatible blood is administered to a patient, it may cause a grave and possibly deadly reaction.